Generate QR code
Open Access
Subscription Access
Features of cardiac damage in illicit drugs users: from pathophysiology to treatment algorithms
https://doi.org/10.30629/0023-2149-2026-104-3-176-183
Abstract
Relevance. In modern society, the spectrum of cardiac surgical pathology that develops in chronic drug users has expanded significantly and is not limited only to infectious lesions of the heart valves. This dictates the need for an in-depth study of the pathophysiological mechanisms of the effects of various narcotic substances on cardiac structures in order to develop a differentiated approach to the treatment of these patients. The literature review concerns the need of development of approach to the treatment of cardiac surgical patients with comorbid past or current drug abuse, depending on the type of narcotic substance used.
Conclusion. The development of a differentiated approach that considers the mechanisms of cardiovascular toxicity of various narcotic substances might help elaborate the ways to reduce the pathological changes yielding in significant improvement in treatment of these patients.
About the Authors
V. V. Krylov
M.F. Vladimirsky Moscow Regional Research and Clinical Institute «MONIKI»
Russian Federation
Russian Federation
Vladislav V. Krylov — Candidate of Medical Sciences, cardiovascular surgeon of the adult’s cardiovascular surgery department and emergency and routine counseling department
Moscow
T. V. Klimenko
National Scientific Center for Narcology, branch of V.P. Serbsky National Medical Research Center for Psychiatry and Narcology of the Ministry of Health of Russian Federation
Russian Federation
Russian Federation
Tatyana V. Klimenko — Doctor of Medical Sciences, professor, director
Moscow
F. S. Shagiakhmetov
National Scientific Center for Narcology, branch of V.P. Serbsky National Medical Research Center for Psychiatry and Narcology of the Ministry of Health of Russian Federation
Russian Federation
Russian Federation
Farid Sh. Shagiakhmetov — Candidate of Medical Sciences, narcologist, researcher
Moscow
References
1. Glushchenko V.A., Irklienko E.K. Cardiovascular morbidity is one of the most important public health problems. Meditsina i organizatsiia zdravookhraneniia. 2019;4(1):56–63. (In Russ.).
2. Morphological diagnosis of narcotic intoxication in forensic medicine. Tutorial for universities. 2nd edition, revised and enlarged. Yu.I. Pigolkin eds. Moscow, 2021:281. (In Russ.).
3. Sorokina V.V. Dynamics of morphological changes in the heart in chronic drug addiction, depending on the length of drug use. Sibirskiy meditsinskiy zhurnal. 2008;1(1):11–15. (In Russ.).
4. Gurevich M.A. Some features of modern infective endocarditis. Almanakh klinicheskoy meditsiny. 2014;35:30–33. (In Russ.).
5. Demko I.V., Pelinovskaya L.I., Mankhayeva M.V. et al. Features of infective endocarditis in injection drug users. Russian Journal of Cardiology. 2019;24(6):97–102. (In Russ.). DOI: 10.15829/1560-4071-2019-6-97-102
6. Chipigina N.S., Shostak N.A., Vinogradova T.L., Malysheva A.M. Infective endocarditis in intravenous drug users. Vestnik RGMU. 2009;7:97–101. (In Russ.).
7. Ponomareva E.Y., Rebrov A.P. Infective endocarditis in intravenous drugs abused patient. Klinicist. 2011;3:83–85. (In Russ.).
8. Verbilo R.I., Hadji Ismail A.I., Sholkova M.V. Diff erences in the course of infective endocarditis in injecting drug users and patients without drug dependence. Cardiology readings — 2016. Materials of the of the 1st scientifi c and practical part-time conference of students and young scientists. Minsk: BSMU, 2016:196–200. Available at: http://rep.bsmu.by/handle/BSMU/12285. (In Russ.).
9. Stolbova M.V., Liscova U.V., Artemova N.E. et al. Features of an infectious endocarditis in injection «salt» addicts. Archive of internal medicine. 2017;7(4):267–270. (In Russ.). DOI: 10.20514/2226-6704-2017-7-4-267-270
10. Shabanov P.D. Fundamentals of Narcology. St. Petersburg: Lan Publishing House, 2002:560. (In Russ.).
11. Malin D.I., Medvedev V.M. Clinical narcology in diagrams, tables and drawings: a textbook, 4th edition. Moscow: Vuzovskaya kniga, 2013:172. (In Russ.).
12. Goffman A.G. Clinical narcology, 2nd edition. Moscow: Meditsinskoye informatsionnoye agentstvo, 2017:376. (In Russ.).
13. Katzung B.G. Basic & clinical pharmacology. McGraw-Hill Medical, 2009:1200.
14. Schatzberg A.F., Nemeroff C.B. The American Psychiatric Publishing Textbook of Psychopharmacology. The American Psychiatric Publishing, 2009:1648.
15. Dawson P., Moffatt J. Cardiovascular toxicity of novel psychoactive drugs: Lessons from the past. Progress in Neuro-Psychopharmacology and Biological Psychiatry. 2012;39(2):244–252. DOI: 10.1016/j.pnpbp.2012.05.003
16. Mas-Morey P., Visser M., Winkelmolen L., Touw D. Clinical Toxicology and Management of Intoxications With Synthetic Cathinones («Bath Salts»). Journal of Pharmacy Practice. 2013;26(4):353–357. DOI: 10.1177/0897190012465949
17. Shagiakhmetov F.Sh., Shamakina I.Yu. «Designer» drugs: stimulants and euphorics. Voprosy narkologii. 2015;1:117–141. (In Russ.).
18. Uyba V.V., Krivorotov D.V., Zabelin M.V. et al. Opioid receptor antagonists. From the present to the future. Meditsina ekstremalnykh situatsiy. 2018; 20(3): 356–370. (In Russ.).
19. Kelly D.J. Cathinone derivatives: a review of their chemistry, pharmacology and toxicology. Drug Testing and Analysis. 2011;3(7– 8):439–453. DOI: 10.1002/dta.313
20. Howlett A.C. The cannabinoid receptors. Prostaglandins and other lipid mediators. 2002;68–69:619–631. DOI: 10.1016/S0090-6980(02)00060-6
21. Saroz Yu., Kho D.T., Glass M. et al. Cannabinoid Receptor 2 (CB2) Signals via G-alpha-s and Induces IL-6 and IL-10 Cytokine Secretion in Human Primary Leukocytes. ACS Pharmacology & Translational Science. 2019;2(6):414–428. DOI: 10.1021/acsptsci.9b00049
22. Hoyer D. 5-HT-2B Receptor / In book: xPharm: The Comprehensive Pharmacology Reference. Philadelphia: Elsevier Saunders, 2007:1– 9. DOI: 10.1016/B978-008055232-3.60132-1
23. Burlew B.S., Weber K.T. Connective tissue and the heart. Functional signifi cance and regulatory mechanisms. Cardiology Clinics. 2000;18(3):435–442. DOI: 10.1016/S0733-8651(05)70154-5
24. Seltenhammer M., Marchart K., Schatz P. et al. Micromorphological changes in cardiac tissue of drug-related deaths with emphasis on chronic illicit opioid abuse. Addiction. 2013;108(7):1287–1295. DOI: 10.1111/add.12106
25. Dettmeyer R., Friedrich K., Schmidt P., Madea B. Heroin-associated myocardial damages — conventional and immunohistochemical investigations. Forensic Science International. 2009;187(1–3):42– 46. DOI: 10.1016/j.forsciint.2009.02.014
26. Darke S., Duflou J., Kaye S. Prevalence and nature of cardiovascular disease in methamphetamine-related death: A national study. Drug and Alcohol Dependence. 2017;179:174–179. DOI: 10.1016/j.drugalcdep.2017.07.001
27. Duflou J. Psychostimulant use disorder and the heart. Addiction. 2019;115(1):175–183. DOI: 10.1111/add.14713
28. Setola V., Hufeisen S.J., Grande-Allen K.J. et al. 3,4-Methylenedi oxymethamphetamine (MDMA, «Ecstasy») Induces Fenfl uramineLike Proliferative Actions on Human Cardiac Valvular Interstitial Cells in Vitro. Molecular pharmacology. 2003;63(6):1223–1229. DOI: 10.1124/mol.63.6.1223
29. Droogmans S., Cosyns B., D'haenenet H. et al. Possible Association Between 3,4-Methylenedioxymethamphetamine Abuse and Valvular Heart Disease. The American Journal of Cardiology. 2007;100(9):1442–1445. DOI: 10.1016/j.amjcard.2007.06.045
30. Andrejak M., Tribouilloy C. Drug-induced valvular heart disease: an update. Archives of Cardiovascular Diseases. 2013;106(5):333–339. DOI: 10.1016/j.acvd.2013.02.003
31. Li C., Xu S., Gotlieb A.I. The response to valve injury. A paradigm to understand the pathogenesis of heart valve disease. Cardiovascular Pathology. 2011;20(3):183–190. DOI: 10.1016/j.carpath.2010.09.008
32. Goldberg E., Grau J.B., Fortier J.H. et al. Serotonin and catecholamines in the development and progression of heart valve diseases. Cardiovascular Research. 2017;113:849–857. DOI: 10.1093/cvr/cvx092
33. Ayme-Dietrich E., Lawson R., Da-Silva S. et al. Serotonin contribution to cardiac valve degeneration: new insights for novel therapies? Pharmacological Research. 2019;140:33–42. DOI: 10.1016/j.phrs.2018.09.009
34. Waldum H., Wahba A. Serotonin — A Driver of Progressive Heart Valve Disease. Frontiers in Cardiovascular Medicine. 2022;9:774573. DOI: 10.3389/fcvm.2022.774573
35. Pathophysiology of heart disease: a collaborative project of medical students and faculty, 5th ed. L.S. Lilly eds. Philadelphia: Lippincott Williams and Wilkins, 2010:461.
36. Voynov V.A. Pathophysiology of the heart and blood vessels. Tutorial. Moscow: Izdatelskiy dom BINOM, 2017:208. (In Russ.).
37. Seferian A., Chaumas M.-C., Savale L. et al. Drugs induced pulmonary arterial hypertension. La Presse Médicale. 2013;42(9):e303– e310. DOI: 10.1016/j.lpm.2013.07.005
38. Kozor R., Grieve S.M., Buchholz S. et al. Regular Cocaine Use Is Associated with Increased Systolic Blood Pressure, Aortic Stiff ness and Left Ventricular Mass in Young Otherwise Healthy Individuals. PLoS One. 2014;9;9(4):e89710. DOI: 10.1371/journal.pone.0089710
39. Wako E., LeDoux D., Mitsumori L., Aldea G.S. The emerging epidemic of methamphetamine-induced aortic dissections. Journal of Cardiac Surgery. 2007;22(5):390–393. DOI: 10.1111/j.1540-8191.2007.00432.x
40. Dean J.H., Woznicki E.M., O'Gara P. et al. Cocaine Related Aortic Dissection: Lessons from the International Registry of Acute Aortic Dissection. The American Journal of Medicine. 2014;127(9):878– 85. DOI: 10.1016/j.amjmed.2014.05.005
41. Iacobellis G., Kemp W. Cardiomyocyte apoptosis in cocaine-induced myocarditis with involvement of bundle of His and left bundle branch. International Journal of Cardiology. 2006;112:116–118. DOI: 10.1016/j.ijcard.2005.08.052
42. Yeo K.K., Wijetunga M., Ito H. et al. The association of methamphetamine use and cardiomyopathy in young patients. The American Journal of Medicine. 2007;120(2):165–171. DOI: 10.1016/j.amjmed.2006.01.024
43. Schurer S., Klingel K., Sandri M. et al. Clinical characteristics, histopathological features, and clinical outcome of methamphetamine-associated cardiomyopathy. JACC Heart Failure. 2017;5:435–445. DOI: 10.1016/j.jchf.2017.02.017
44. Butterfield M., Riguzzi C., Frenkel O., Nagdev A. Stimulant-Related Takotsubo Cardiomyopathy. The American Journal of Emergency Medicine. 2015;33(3):476.e1–476.e3. DOI: 10.1016/j.ajem.2014.08.058
45. Diercks D., Owen K., Patel T.Y. et al. 181 Cocaine and Methamphetamine Cardiomyopathy: Do Similar Drugs Produce Similar Damage. Annals of Emergency Medicine. 2011;58(4):S238. DOI: 10.1016/j.annemergmed.2011.06.209
46. Varga Z., Ferdinandy P., Liaudet L., Pacher P. Drug-induced mitochondrial dysfunction and cardiotoxicity. AJP Heart and Circulatory Physiology. 2015;309(9):H1453–H1467. DOI: 10.1152/ajpheart.00554.2015
47. Walsh K.B., Andersen H.K. Molecular Pharmacology of Synthetic Cannabinoids: Delineating CB1 Receptor-Mediated Cell Signaling. International Journal of Molecular Sciences. 2020;21(17):6115. DOI: 10.3390/ijms21176115
48. Paul A.B.M., Simms L., Amini S., Paul A.E. Teens & Spice: A Review of Synthetic Cannabinoid Associated Fatalities in Adolescents. Journal of Forensic Sciences. 2017;63(4):1321–1324. DOI: 10.1111/1556-4029.13704
49. Boland D.M., Reidy L.J., Seither J.M. et al. Forty-Three Fatalities Involving the Synthetic Cannabinoid, 5-Fluoro-ADB: Forensic Pathology and Toxicology Implications. Journal of Forensic Sciences. 2019;65(1):170–182. DOI: 10.1111/1556-4029.14098
50. Iversen L., Gibbons S., Treble R. et al. Neurochemical profi les of some novel psychoactive substances. European Journal of Pharmacology. 2013;700(1–3):147–151. DOI: 10.1016/j.ejphar.2012.12.006
51. Yoon K.S., Gu S.M., Cha H.J. et al. 25I-NBOMe, a phenethylamine derivative, induces adverse cardiovascular eff ects in rodents: possible involvement of p21 (CDC42/RAC)-activated kinase 1. Drug and Chemical Toxicology. 2022;45(2):898–906. DOI: 10.1080/01480545.2020.1784924
52. Droogmans S., Roosens B., Cosyns B. et al. Cyproheptadine prevents pergolide-induced valvulopathy in rats: An echocardiographic and histopathological study. AJP Heart and Circulatory Physiology. 2009;296(6):H1940–H1948. DOI: 10.1152/ajpheart.01177.2008
53. Hutcheson J.D., Setola V., Roth B., Merryman W.D. Serotonin Receptors and Heart Valve Disease — it was meant 2B. Pharmacology & Therapeutics. 2011;132(2):146–157. DOI: 10.1016/j.pharmthera.2011.03.008
54. Shahid M., Walker G.B., Zorn S.H., Wong E.H. Asenapine: a novel psychopharmacologic agent with a unique human receptor signature. Journal of Psychopharmacology. 2009;23(1):65–73. DOI: 10.1177/0269881107082944
55. Petrova N.N., Shagiakh metov F.S., Borukaev R.R. Trazodone — a multi-faceted antidepressant drug. Psychiatry and psychopharmacotherapy. 2021;23(3):40–46. (In Russ.).
56. Bokeriia L.A., editor. Cardiovascular Surgery Lectures, 3rd edition, revised and supplemented. Moscow: NCSSH im. A.N. Bakuleva RAMN, 2013:764. (In Russ.).
57. Kouchoukos N.T., Blackstone E.H., Hanley F.L., Kirklin J.K. Kirklin/Barratt-Boyes cardiac surgery: morphology, diagnostic criteia, natural history, techniques, results, and indications, 4th ed, 2-Volume set. Philadelphia: Elsevier Saunders, 2013;1–2:2256.
58. Krylov V.V. Organization of cardiac surgical care. Problems and possible solutions. Medical Technologies. Assessment and Choice. 2022;44(3):67–74. (In Russian). DOI: 10.17116/medtech20224403167
Review
For citations:
Krylov V.V., Klimenko T.V., Shagiakhmetov F.S. Features of cardiac damage in illicit drugs users: from pathophysiology to treatment algorithms. Clinical Medicine (Russian Journal). 2026;104(3):176-183. (In Russ.) https://doi.org/10.30629/0023-2149-2026-104-3-176-183
Views:
188
JATS XML
Email this article 